Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.38 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2894902 | 0.83 | SLC6A5 (0.35) | PDFALDH1A1LMNAUSP2CYP3A4 | |
| SCHEMBL13026190 | 0.80 | KMT2A (0.35) | ALDH1A1LMNAUSP2CYP3A4MAPT | |
| SCHEMBL13026184 | 0.80 | KMT2A (0.35) | ALDH1A1LMNAUSP2CYP3A4MAPT | |
| SCHEMBL10274067 | 0.72 | CTSK (0.57) | CTSK | |
| SCHEMBL12607856 | 0.66 | CTSK (0.57) | CTSK | |
| SCHEMBL13350750 | 0.64 | ADH1B (0.36) | ALDH1A1LMNAUSP2CYP3A4MAPT | |
| SCHEMBL28760000 | 0.64 | ALDH1A1 (0.49) | CTSKALDH1A1LMNAMAPT | |
| SCHEMBL2457118 | 0.63 | TGM2 (0.42) | CTSKALDH1A1LMNAUSP2CYP3A4 | |
| SCHEMBL13268215 | 0.62 | CTSK (0.43) | CTSKALDH1A1LMNAUSP2CYP3A4 | |
| SCHEMBL4530365 | 0.62 | PDF (0.37) | CTSKPDFALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286185-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | CTSK 121/4885PDF 1052/4885ALDH1A1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.